JP2005506275A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2005506275A5 JP2005506275A5 JP2002548141A JP2002548141A JP2005506275A5 JP 2005506275 A5 JP2005506275 A5 JP 2005506275A5 JP 2002548141 A JP2002548141 A JP 2002548141A JP 2002548141 A JP2002548141 A JP 2002548141A JP 2005506275 A5 JP2005506275 A5 JP 2005506275A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- polypeptide
- fgf
- nucleotide sequence
- composition according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 62
- 239000002773 nucleotide Substances 0.000 claims 36
- 125000003729 nucleotide group Chemical group 0.000 claims 36
- 229920001184 polypeptide Polymers 0.000 claims 36
- 102000004196 processed proteins & peptides Human genes 0.000 claims 36
- 108090000765 processed proteins & peptides Proteins 0.000 claims 36
- 150000001413 amino acids Chemical class 0.000 claims 23
- 108050002085 Fibroblast growth factor 20 Proteins 0.000 claims 18
- 102100031361 Fibroblast growth factor 20 Human genes 0.000 claims 18
- 108090000367 Fibroblast growth factor 9 Proteins 0.000 claims 18
- 102100037665 Fibroblast growth factor 9 Human genes 0.000 claims 18
- 230000000694 effects Effects 0.000 claims 12
- 239000012634 fragment Substances 0.000 claims 12
- 239000000203 mixture Substances 0.000 claims 12
- 239000003814 drug Substances 0.000 claims 10
- 201000006417 multiple sclerosis Diseases 0.000 claims 8
- 101000846532 Homo sapiens Fibroblast growth factor 20 Proteins 0.000 claims 6
- 101001027380 Homo sapiens Fibroblast growth factor 9 Proteins 0.000 claims 6
- 102000053868 human FGF20 Human genes 0.000 claims 6
- 102000057240 human FGF9 Human genes 0.000 claims 6
- 230000002163 immunogen Effects 0.000 claims 6
- 102000039446 nucleic acids Human genes 0.000 claims 6
- 108020004707 nucleic acids Proteins 0.000 claims 6
- 150000007523 nucleic acids Chemical class 0.000 claims 6
- 201000011452 Adrenoleukodystrophy Diseases 0.000 claims 4
- 206010002329 Aneurysm Diseases 0.000 claims 4
- 208000030939 Chronic inflammatory demyelinating polyneuropathy Diseases 0.000 claims 4
- 208000032843 Hemorrhage Diseases 0.000 claims 4
- 208000023105 Huntington disease Diseases 0.000 claims 4
- 206010061216 Infarction Diseases 0.000 claims 4
- 208000032382 Ischaemic stroke Diseases 0.000 claims 4
- 102000009030 Member 1 Subfamily D ATP Binding Cassette Transporter Human genes 0.000 claims 4
- 108010049137 Member 1 Subfamily D ATP Binding Cassette Transporter Proteins 0.000 claims 4
- 208000003926 Myelitis Diseases 0.000 claims 4
- 206010028570 Myelopathy Diseases 0.000 claims 4
- 208000002774 Paraproteinemias Diseases 0.000 claims 4
- 206010042928 Syringomyelia Diseases 0.000 claims 4
- 208000034158 bleeding Diseases 0.000 claims 4
- 230000000740 bleeding effect Effects 0.000 claims 4
- 201000005795 chronic inflammatory demyelinating polyneuritis Diseases 0.000 claims 4
- 201000002491 encephalomyelitis Diseases 0.000 claims 4
- 230000007574 infarction Effects 0.000 claims 4
- 208000014674 injury Diseases 0.000 claims 4
- 210000000944 nerve tissue Anatomy 0.000 claims 4
- 206010036807 progressive multifocal leukoencephalopathy Diseases 0.000 claims 4
- 230000001737 promoting effect Effects 0.000 claims 4
- 210000000278 spinal cord Anatomy 0.000 claims 4
- 208000020431 spinal cord injury Diseases 0.000 claims 4
- 230000004083 survival effect Effects 0.000 claims 4
- 208000011580 syndromic disease Diseases 0.000 claims 4
- 230000000451 tissue damage Effects 0.000 claims 4
- 231100000827 tissue damage Toxicity 0.000 claims 4
- 230000008733 trauma Effects 0.000 claims 4
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US25183700P | 2000-12-08 | 2000-12-08 | |
| US10/005,646 US20020151496A1 (en) | 2000-12-08 | 2001-12-07 | Novel fibroblast growth factors |
| PCT/US2001/047350 WO2002046424A2 (en) | 2000-12-08 | 2001-12-10 | Fibroblast growth factors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2005506275A JP2005506275A (ja) | 2005-03-03 |
| JP2005506275A5 true JP2005506275A5 (cg-RX-API-DMAC7.html) | 2005-06-09 |
Family
ID=26674594
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2002548141A Pending JP2005506275A (ja) | 2000-12-08 | 2001-12-10 | 新規線維芽細胞増殖因子 |
Country Status (21)
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7253266B2 (en) | 1999-07-27 | 2007-08-07 | Curagen Corporation | Polypeptides of FGF-CX |
| US6982250B2 (en) | 2000-11-06 | 2006-01-03 | Curagen Corporation | Methods of prevention and treatment of inflammatory bowel disease |
| US7189693B2 (en) | 2000-11-06 | 2007-03-13 | Curagen Corporation | Treatment of inflammatory bowel disease using fibroblast growth factor CX polypeptides |
| WO2003059270A2 (en) * | 2002-01-15 | 2003-07-24 | Eli Lilly And Company | Method for reducing morbidity and mortality in critically ill patients |
| EP1608411B1 (en) * | 2003-04-01 | 2010-09-29 | United States Government as represented by the Department of Veteran's Affaires | Stem-cell, precursor cell, or target cell-based treatment of multi-organ failure. |
| WO2004105787A1 (en) * | 2003-05-28 | 2004-12-09 | The University Of Kyoto | Methods of using combinations of egf-2 and egf-20 to treat central nervous system disorders |
| LT2726511T (lt) | 2011-07-01 | 2019-11-11 | Ngm Biopharmaceuticals Inc | Kompozicijos, panaudojimai ir būdai, skirti metabolinių sutrikimų ir ligų gydymui |
| US9290557B2 (en) | 2012-11-28 | 2016-03-22 | Ngm Biopharmaceuticals, Inc. | Compositions comprising variants and fusions of FGF19 polypeptides |
| AU2013352363B2 (en) | 2012-11-28 | 2018-04-12 | Ngm Biopharmaceuticals, Inc. | Compositions and methods for treatment of metabolic disorders and diseases |
| AU2013370404B2 (en) | 2012-12-27 | 2017-11-02 | Ngm Biopharmaceuticals, Inc. | Methods for modulating bile acid homeostasis and treatment of bile acid disorders and diseases |
| US9273107B2 (en) | 2012-12-27 | 2016-03-01 | Ngm Biopharmaceuticals, Inc. | Uses and methods for modulating bile acid homeostasis and treatment of bile acid disorders and diseases |
| MX377380B (es) | 2013-10-28 | 2025-03-10 | Ngm Biopharmaceuticals Inc | Modelos de cáncer y métodos asociados. |
| SI3097122T1 (sl) | 2014-01-24 | 2020-07-31 | Ngm Biopharmaceuticals, Inc. | Protitelesa, ki se vežejo v domeni beta klotho 2, in metode za njihovo uporabo |
| WO2015183890A2 (en) | 2014-05-28 | 2015-12-03 | Ngm Biopharmaceuticals, Inc. | Methods and compositions for the treatment of metabolic disorders and diseases |
| EP3155005A4 (en) | 2014-06-16 | 2018-07-11 | NGM Biopharmaceuticals, Inc. | Methods and uses for modulating bile acid homeostasis and treatment of bile acid disorders and diseases |
| UA123763C2 (uk) | 2014-10-23 | 2021-06-02 | Енджіем Байофармасьютикалз, Інк. | Фармацевтична композиція для контролю або лікування захворювання або порушення, пов’язаного з fgf19 |
| US10434144B2 (en) | 2014-11-07 | 2019-10-08 | Ngm Biopharmaceuticals, Inc. | Methods for treatment of bile acid-related disorders and prediction of clinical sensitivity to treatment of bile acid-related disorders |
| WO2017019957A2 (en) | 2015-07-29 | 2017-02-02 | Ngm Biopharmaceuticals, Inc. | Binding proteins and methods of use thereof |
| CA3003616C (en) | 2015-11-09 | 2020-07-28 | Ngm Biopharmaceuticals, Inc. | Methods for treatment of bile acid-related disorders |
| CA3034399A1 (en) | 2016-08-26 | 2018-03-01 | Ngm Biopharmaceuticals, Inc. | Methods of treating fibroblast growth factor 19-mediated cancers and tumors |
| CN107050428B (zh) * | 2017-03-23 | 2020-05-05 | 温州医科大学 | Fgf20药物及其对脑创伤的治疗应用 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5A (en) * | 1836-08-10 | Thomas Blanchard | Machine for mortising solid wooden shells of ships' tackle-blocks | |
| WO2000060085A1 (en) * | 1999-04-02 | 2000-10-12 | Millennium Pharmaceuticals, Inc. | Fibroblast growth factor-20 |
| JP2003512841A (ja) * | 1999-10-22 | 2003-04-08 | カイロン コーポレイション | ヒトおよびラットｆｇｆ−２０遺伝子および遺伝子発現産物 |
| JP2003516731A (ja) * | 1999-11-18 | 2003-05-20 | カイロン コーポレイション | ヒトｆｇｆ−２１遺伝子および遺伝子発現産物 |
| AU2001262934A1 (en) * | 2000-06-01 | 2001-12-11 | Eli Lilly And Company | Human fgf-20 nucleic acids and polypeptides |
| WO2002002625A2 (en) * | 2000-07-03 | 2002-01-10 | Curagen Corporation | Novel fibroblast growth factors and nucleic acids encoding same |
-
2001
- 2001-12-07 US US10/005,646 patent/US20020151496A1/en not_active Abandoned
- 2001-12-10 SK SK701-2003A patent/SK7012003A3/sk unknown
- 2001-12-10 BR BR0116507-0A patent/BR0116507A/pt not_active IP Right Cessation
- 2001-12-10 JP JP2002548141A patent/JP2005506275A/ja active Pending
- 2001-12-10 CN CNA018202993A patent/CN1518597A/zh active Pending
- 2001-12-10 EE EEP200300269A patent/EE200300269A/xx unknown
- 2001-12-10 SI SI200120066A patent/SI21372A/sl not_active IP Right Cessation
- 2001-12-10 WO PCT/US2001/047350 patent/WO2002046424A2/en not_active Ceased
- 2001-12-10 HU HU0400657A patent/HUP0400657A1/hu unknown
- 2001-12-10 CZ CZ20031570A patent/CZ20031570A3/cs unknown
- 2001-12-10 MX MXPA03005142A patent/MXPA03005142A/es not_active Application Discontinuation
- 2001-12-10 KR KR10-2003-7007614A patent/KR20040052442A/ko not_active Ceased
- 2001-12-10 RU RU2003119657/14A patent/RU2329058C2/ru not_active IP Right Cessation
- 2001-12-10 CA CA002431374A patent/CA2431374A1/en not_active Abandoned
- 2001-12-10 IL IL15625901A patent/IL156259A0/xx unknown
- 2001-12-10 EP EP01995460A patent/EP1389237A2/en active Pending
- 2001-12-10 AU AU2603402A patent/AU2603402A/xx active Pending
- 2001-12-10 PL PL01366158A patent/PL366158A1/xx not_active Application Discontinuation
-
2003
- 2003-06-06 BG BG107888A patent/BG107888A/bg unknown
- 2003-06-06 NO NO20032573A patent/NO20032573L/no not_active Application Discontinuation
- 2003-07-07 ZA ZA2003/05236A patent/ZA200305236B/en unknown
-
2007
- 2007-06-22 US US11/821,191 patent/US20080057076A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2005506275A5 (cg-RX-API-DMAC7.html) | ||
| RU2003119657A (ru) | Новые факторы роста фибробластов | |
| JP2002532432A5 (cg-RX-API-DMAC7.html) | ||
| NZ601544A (en) | Combination therapy for the treatment of ocular neovascular disorders | |
| EA200601121A1 (ru) | Мутеины фактора роста фибробластов 21 | |
| WO2000021548A3 (en) | Angiogenically effective unit dose of fgf and method of administering | |
| JP2004518632A5 (cg-RX-API-DMAC7.html) | ||
| JP2003500040A5 (cg-RX-API-DMAC7.html) | ||
| NO20051934L (no) | Sfingosin-1-fosfatreseptoragonister ved behandling av demyelinerende lidelser. | |
| BR9810944A (pt) | Controle de sìndrome de intestino acìdico | |
| BR9811825A (pt) | Uso de lactobacillus para redução do nìvel de fibrinogênio no sangue | |
| JP2002543065A5 (cg-RX-API-DMAC7.html) | ||
| JP2006524034A5 (cg-RX-API-DMAC7.html) | ||
| BR0014155A (pt) | Prevenção da miocardite, do aborto e da infecção intrauterina, associados com o circovìrus-2 porcino | |
| JP2004527551A5 (cg-RX-API-DMAC7.html) | ||
| RU2002130200A (ru) | Композиции для доставки лекарственного средства | |
| JP2002536016A5 (cg-RX-API-DMAC7.html) | ||
| JP2003533188A5 (cg-RX-API-DMAC7.html) | ||
| ES2242858T3 (es) | Utilizacion de toxina botulinica para obtener un producto que se utiliza en patologias articulares, particularmente coxartrosis, epicondilitis y patologia de la capsula de los musculos rotadores. | |
| JP2009500045A5 (cg-RX-API-DMAC7.html) | ||
| KR970701724A (ko) | 스타니어스 단백질인 스타니오칼신의 소체(Corpuscles of stannius protein, stanniocalcin) | |
| JP2002530353A5 (cg-RX-API-DMAC7.html) | ||
| JP2004521076A5 (cg-RX-API-DMAC7.html) | ||
| BR0111852A (pt) | Nova interferona para o tratamento de esclerose múltipla | |
| WO2002058720A3 (en) | Angiogenically effective unit dose of fgf-2 and method of use |